Search / Trial NCT00002531

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Launched by JOHANN WOLFGANG GOETHE UNIVERSITY HOSPITAL · Feb 13, 2004

Trial Information

Current as of December 07, 2024

Unknown status

Keywords

Untreated Adult Acute Lymphoblastic Leukemia T Cell Adult Acute Lymphoblastic Leukemia B Cell Adult Acute Lymphoblastic Leukemia Non T, Non B Adult Acute Lymphoblastic Leukemia

ClinConnect Summary

OBJECTIVES: I. Develop risk-adapted therapy for patients with low-risk, high-risk, T-cell, or B-cell acute lymphocytic leukemia (ALL). II. Determine the complete remission rate in these patients treated with the following strategies: increased doses of cyclophosphamide during induction and reinduction, early use of high-dose cytarabine plus mitoxantrone (for high-risk patients), and increased doses of methotrexate (for B-cell ALL patients). III. Determine the duration of remission and survival of patients in all risk groups treated with intensified consolidation and subtype-specific chemoth...

Gender

ALL

Eligibility criteria

  • DISEASE CHARACTERISTICS: Diagnosis of low-risk acute lymphocytic leukemia (ALL) (common ALL or pre-B-cell) Must meet 1 of the following 2 conditions: Age 51 to 65 and meets the following criteria: No mediastinal mass No T-cell or B-cell disease Age 15 to 50 and meets the following criteria: Philadelphia chromosome (Ph) negative bcr-abl negative Initial WBC less than 30,000/mm3 OR Diagnosis of T-cell ALL with or without mediastinal involvement Age 15 to 50 OR Diagnosis of high-risk ALL (common ALL or pre-B-cell) Age 15 to 50 and meets 1 of the following criteria: Ph positive bcr-abl positive Pre-pre-B-cell disease, i.e., t(4;11) Initial WBC greater than 30,000/mm3 OR Diagnosis of B-cell ALL
  • PATIENT CHARACTERISTICS: Age: See Disease Characteristics 15 to 65 Performance status: Not specified Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: No renal failure Cardiovascular: No cardiomyopathy Other: HIV-1 and HIV-2 negative No severe psychiatric disease
  • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytostatic drugs except vincristine Endocrine therapy: Prior corticosteroids allowed Radiotherapy: Not specified Surgery: Not specified Other: No more than 2 weeks of prior therapy No other prior cytostatic drugs

Trial Officials

Dieter Hoelzer, MD, PhD

Study Chair

Johann Wolfgang Goethe University Hospital

About Johann Wolfgang Goethe University Hospital

Johann Wolfgang Goethe University Hospital, located in Frankfurt am Main, Germany, is a prominent academic medical center affiliated with Goethe University. Renowned for its commitment to advancing healthcare through innovative research and clinical excellence, the hospital serves as a vital hub for clinical trials and medical studies. It integrates cutting-edge technology with a multidisciplinary approach, facilitating collaboration among healthcare professionals to enhance patient outcomes. The hospital is dedicated to ethical research practices and adheres to stringent regulatory standards, ensuring the safety and well-being of trial participants while contributing to the advancement of medical science.

Locations

Frankfurt, , Germany

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials